- Home
- FLC vs UNCY Comparison
FLC vs UNCY Comparison
Compare FLC & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | UNCY |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0M | 145.3M |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FLC | UNCY |
|---|---|---|
| Price | $16.66 | $8.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 19.8K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.89 | $3.72 |
| 52 Week High | $18.09 | $8.74 |
Technical Indicators
Market Signals| Indicator | FLC | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 39.21 | 58.30 |
| Support Level | $16.63 | $6.77 |
| Resistance Level | $17.68 | $8.40 |
| Average True Range (ATR) | 0.15 | 0.61 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 28.23 | 76.54 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.